Moleculin Biotech is trading at $9.75, up 5.23%, in after-hours trading; no confirmed company-specific announcement explains the move.

  • It closed October 27 at $9.27, up 30.77%; after-hours trading extended the gain.
  • The latest identified update was October 20, covering MIRACLE trial progress and expected first-quarter 2027 data; it does not establish a cause.
  • Broader markets, including the Nasdaq, advanced, but evidence does not establish that sentiment drove the stock’s after-hours rise.